Clarinex is widely used and popular because of its non-drowsy characteristic. Many antihistamines tell users to avoid machinery or driving while taking it, but Clarinex does not. This drug was also the first to boast that grapefruit juice did not affect its absorption.
Prior to the approval of Clarinex in the United States, numerous clinical studies were conducted in over 4,000 adults and children. This included studies looking at the effects of Clarinex on seasonal allergy symptoms, perennial allergy symptoms, and chronic urticaria. In these studies, people taking the drug had improved relief, compared to the group of people not taking the medicine.
Schering-Plough Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved CLARINEX-D(R) 24 HOUR (desloratadine 5mg and pseudoephedrine sulfate USP 240 mg) Extended Release Tablets for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis (outdoor allergies), including nasal congestion, in patients 12 years of age and older.
|
